Pharmaceutical companies are becoming increasingly focused on product life cycle management due to expiring patents, generic encroachment and declining new drug pipelines. It is estimated that over 80 major drugs representing over $95 billion in 2006 sales will lose patent and/or exclusivity protection over the next 5-7 years. 

Utilizing MonoSol Rx’s PharmFilm® technology, pharmaceutical companies may be able to extend patent life cycles and develop new markets for proven drugs, helping to protect billions of dollars of revenues by preempting generic competition and leveraging the film dosage form. The opportunity for film formulations is substantial; MonoSol Rx’s PharmFilm® drug delivery technology can be applied to a large pool of drugs due to its ability to carry a variety of active pharmaceutical ingredients.

Film is more stable, durable and quicker dissolving than other conventional dosage forms. The technology enables differentiation within large therapeutic categories and potentially improves patient compliance. In addition, the sublingual and buccal delivery of a given drug via PharmFilm® has the potential to improve the onset of action, lower dosing and enhance the efficacy and safety profile.